TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CLEO Diagnostics Ltd ( (AU:COV) ) has provided an update.
Cleo Diagnostics Ltd announced significant progress in its June 2025 Quarterly Activities Report, highlighting ongoing U.S. clinical trials and completion of alpha testing for its ovarian cancer diagnostic test. The company has secured access to renowned biobanks to support pivotal studies, strengthening its regulatory and clinical pathway. These developments are crucial for CLEO’s planned FDA submission and aim to accelerate the commercialization of its diagnostic test, potentially impacting clinical adoption and payer reimbursement.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd is an ovarian cancer diagnostics company focused on developing a simple and accurate blood test for the early detection of ovarian cancer. The company is engaged in clinical trials and strategic partnerships to enhance its diagnostic capabilities and regulatory submissions.
Average Trading Volume: 65,541
Technical Sentiment Signal: Buy
See more data about COV stock on TipRanks’ Stock Analysis page.